Mikhail Blagosklonny is a scientist of cancer and aging. He teaches oncology in the Institute of the Roswell Park Cancer. Mikhail went to study at First Pavlov State Medical University, where he obtained a medical degree specializing in Internal Medicine. He also studied Experimental Cardiology and Medicine at Ph.D. level in the same university. Mikhail has served in the Institute of Ordway Research as their senior scientist. In 2002, he joined New York Medical College in Valhalla, where he was given the role of an associate medical professor.
In 2009, Mikhail moved to Roswell Park Cancer Institute as the oncology professor. Mikhail has amassed useful skills and knowledge from the different medical institutes he has worked, which makes him an excellent oncology professor. Cancer, biogerontology, anti-ageing drugs, signal transduction, clinical investigation, molecular biology, ontogenesis, apoptosis, tumor suppressors, and targeted cancer therapies are some of the primary research interests for Mikhail. Biogerontology refers to the mechanisms that bring about aging. Visit ResearchGate to keep up to date with Mikhail’s latest work.
Rapamycin; the Drug That Treats Aging
For many years now, there has been no breakthrough in medical industry to establish a specific drug that can prevent or “cure” aging. Scientists all over the world had held on the notion that, aging is a permanent functional decline caused by damage to molecules, and can never be prevented or cured. However, it is now proven that it is possible to treat aging, with the new breakthrough named the Hyperfunction theory. The theory, which was proposed by Mikhail eight years ago, argues that aging is a continuous growth and development that is caused by target signaling pathways like the target of rapamycin.
After the eight years of combined research in DNA damage response, genetic control and repair, longevity regulation, aging evolution, the function of signal transduction pathways and their role in human aging, and cell stress biology, Mikhail has proven that human aging is preventable and treatable. He applied the signal pathways such as (Target of Rapamycin) knowledge and methodology and created TOR-based model that predicts rapalogs such as rapamycin used to prevent diseases and treat aging. The new medication can be used to extend human health life span when employed in right schedules and doses. Check Mikhail’s profile in LinkedIn
Career as a Writer
As the writer of the new aging treatment theory, Mikhail Blagosklonny believes that with accurate and profound research it is possible to prevent cancer and aging. He has also written books, journals, and published articles about chemotherapeutic and cyclotherapy engineering and other sensitive sectors dealing with cancer topic. Mikhail’s resilience, hardware, and passion for humanity and a cancer-free world have put him on the map of the most sought-after oncology researchers and doctors around the globe. He sits on the editorial board of Cell Differentiation and Death. He also serves as the chief editor for the Oncotarget.